Imbue Botanicals Signs a Co-Marketing Agreement With Endocanna Health
The cannabidiol company and DNA tester will co-market CBD products.
Imbue Botanicals, LLC, of Palm Springs, California, has finalized an agreement with Los Angeles California-based Endocanna Health, Inc, to co-market direct-to-consumer cannabidiol (CBD) products and to co-market to 1 of Imbue’s major domains: independent pharmacies.
Imbue Botanicals offers an extensive line of premium CBD products produced from organically grown Colorado hemp, including CBD capsules, lotions, salves, and tinctures, for both people and pets.
Endocanna Health is the maker of the Cannabinoid DNA Variant Test, a comprehensive personalized cannabis DNA test developed by a team of scientists and specialists at the biotechnology research company. This direct-to-consumer DNA test kit analyzes an individual's DNA markers and provides them with science-backed consumer recommendations based on their specific DNA.
“We're excited about introducing Imbue Botanicals to our customers and look forward to working with Imbue’s independent pharmacy and retail clientele to help them make more informed buying decisions,” Len May, Endocanna Health's chief executive and co-founder said in a statement.
“This co-marketing agreement will benefit both companies and will provide many alternative health solutions for our customers. We wanted a CBD product line to partner with that was U.S. grown and manufactured, a partner with innovative designs and branding, and above all, a partner with an efficacy that matches our corporate philosophy," May said.
"We found that in Imbue Botanicals," he said.
“We’re thrilled to be aligned with such a forward-thinking company like Endocanna Health,” Tom Bauer, managing partner for Imbue Botanicals, said in a statement. “Having this kind of arrangement for 2 companies that are so committed to patient care is truly a win-win.”
The co-marketing agreement began in October 2018.